贝伐珠单抗注射液联合盐酸埃克替尼片治疗中晚期非小细胞肺癌的临床疗效及安全性分析被引量：8

Clinical efficacy and safety analysis of bevacizumab injection combined with ectinib hydrochloride in the treatment of advanced non-small cell lung cancer

下载PDF

导出

摘要目的分析讨论贝伐珠单抗注射液联合盐酸埃克替尼片治疗中晚期非小细胞肺癌的临床疗效及安全性。方法选择某院治疗的72例中晚期非小细胞肺癌患者(2017年12月~2018年12月)展开研究,以随机法将患者均分为观察组与参照组,各有36例。参照组接受盐酸埃克替尼片治疗,观察组接受贝伐珠单抗注射液联合盐酸埃克替尼片治疗。结果观察组总缓解率高于参照组(P<0.05);两组患者治疗前的血清肿瘤标志物水平比较无统计学意义;经治疗,观察组VEGF(血管内皮生长因子)、CA125(糖类抗原125)以及CYFRA21-1(细胞角质白19片段)等血清肿瘤标志物水平均低于对照组(P<0.05);观察组血小板减少、白细胞降低、蛋白尿、胃肠道反应等毒副反应发生率均低于参照组(P<0.05)。结论对中晚期非小细胞肺癌采取贝伐珠单抗注射液联合盐酸埃克替尼片治疗,可有效降低血清肿瘤标志物水平以及毒副反应,疗效显著。 Objective To analyze the clinical efficacy and safety of bevacizumab injection combined with ectinib hydrochloride tablets in the treatment of advanced non-small cell lung cancer.Methods A total of 72 patients with intermediate and advanced non-small cell lung cancer(December 2017~December 2018)treated in a hospital were selected to conduct a study.The patients were randomly divided into the observation group and the reference group,with 36 cases each.The reference group received ectinib hydrochloride tablets,and the observation group received bevacizumab injection combined with ectinib hydrochloride tablets.Results The total remission rate in the observation group was higher than that in the reference group(P<0.05).The serum tumor marker levels before treatment in the two groups were not statistically significant.After treatment,the observation group had VEGF(vascular endothelial growth factor)and CA125(sugars antigen 125)and CYFRA21-1(cell keratin white 19 fragment)and other serum tumor markers were lower than the control group(P<0.05);The incidence of thrombocytopenia,leukopenia,proteinuria,gastrointestinal reactions and other toxic side effects in the observation group were lower than those in the reference group(P<0.05).Conclusion Bevacizumab injection combined with ectinib hydrochloride for advanced non-small cell lung cancer can effectively reduce serum tumor marker levels and toxic and side effects,and has a significant effect.

作者张国耀阮转浓 ZHANG Guo-yao;RUAN Zhuan-nong(Xinhui District People's Hospital,Jiangmen City,Jiangmen 529100,China)

机构地区江门市新会区人民医院

出处《中国处方药》 2020年第3期104-105,共2页 Journal of China Prescription Drug

关键词贝伐珠单抗注射液盐酸埃克替尼片中晚期非小细胞肺癌临床疗效安全性 Bevacizumab injection Ectinib hydrochloride tablets Advanced stage Non-small cell lung cancer Clinical efficacy Safety

分类号 R734.2 [医药卫生—肿瘤]